Starting the year with just $2 million in cash and almost no revenue in sight, Navidea Biopharmaceuticals Inc. is counting on an ongoing fundraising effort to keep its doors open and finally get a "promising" drug through regulatory approval.
Board members of the Dublin biotechnology firm are "actively engaged" in talks with sources of outside capital, said Dr. Michael Rosol, chief medical officer, in a recorded webinar with investors this week after reporting larger 2022 net loss than the prior…
